进展期胃癌靶向治疗的研究进展  

Targeted Therapies for Advanced Gastric Cancer: the Current Status

作　　者：安艳新[1] 王菁[2] 刘家良[1] 吉棚[1] 张小桥[1] 

机构地区：[1]济南军区总医院普通外科,山东济南250031 [2]第四军医大学口腔医学院修复科,陕西西安710032

出　　处：《现代生物医学进展》2013年第21期4197-4200,共4页Progress in Modern Biomedicine

基　　金：国家自然科学基金项目(30973410);济南军区总医院院长基金项目(青年基金20110301)

摘　　要：胃癌是消化系统最常见的恶性肿瘤之一,全球每年胃癌新发病例数接近百万,严重影响着人类健康。近年来医学领域发展迅速,不管是胃癌的手术方式,还是放疗、化疗等治疗手段均获得了较大提高。但是由于缺乏有效早期诊断方法,大多数胃癌患者确诊时已进入疾病晚期,所以尽管医学技术不断发展,胃癌的死亡率依然居高不下。随着对胃癌分子机制的不断深入研究,一种直接作用于胃癌主要信号转导通路上某一特定靶点的新型治疗方式--分子靶向治疗逐渐成为当前肿瘤研究的热点。目前已有多种单克隆抗体及小分子靶向药物进入临床,用于人体多种肿瘤的治疗并呈现较好疗效。分子靶向治疗的出现为进展期肿瘤患者带来了新的希望。本文主要就进展期胃癌分子靶向治疗现状以及最新研究进展作一综述。Gastric carcinoma,one of the most frequent malignancies of digestive system,has a seriously influence on human health.Nearly one million new cases are diagnosed each year.With the fast development of medicine,not only remarkably advances in surgical techniques,but also in chemoradiotherapy over the past few years.However,due to lack of clearly deifined technique on early diagnosis,the majority of GC patients are diagnosed at an advanced stage of disease,the prognosis for GC patients with late-stage disease remains poor.With emerging understanding of the molecular pathways about GC,a new method-molecular targeted therapy that designed to interfere with specific molecular events in the key pathways of tumor growth and progression,has become the primary focus of therapeutic cancer research.Now there are some monoclonal antibodies and small molecular targeted drugs have been used to treat tumors of human.The clinical trails,to some extent,find that patients can benefit from targeted therapy which brings new hope for the patients with advanced cancer.In this review we describe the current status of targeted therapies in the treatment of GC.

关 键 词：胃癌 靶向治疗 单克隆抗体 研究进展 

分 类 号：R735.2[医药卫生—肿瘤]